Dr. Jeffrey Anderson
Claim this profileIntermountain Medical Center
Studies Cardiovascular Disease
Studies Health Behaviors
4 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Jeffrey Anderson is currently running
PET Stress Test vs CAC Scan
for Coronary Artery Disease
The cost of medical care in the United States far exceeds that of all other advanced economies and continues to accelerate at a rate unacceptable to our society, due primarily to the high costs of new imaging technologies and novel drugs (1). Cardiac positron emission tomography (PET) imaging is a powerful new modality for the non-invasive detection of provocable coronary ischemia in patients with low to intermediate-risk chest pain or its equivalent. Intermountain Medical Center (IMC) is performing approximately 6000 clinical cardiac PET scans annually. However, cardiac PET scans are expensive (i.e., billed at >$5,000/scan, average receivable revenue $1500-$2000/scan). Coronary artery calcium (CAC) is a sensitive marker of coronary atherosclerosis. A CAC scan (CACS), performed by multislice computed tomography (CT), is a relatively inexpensive (~$70-$150/scan), low-radiation dose test that marks the presence of coronary atherosclerotic plaque. The absence of CAC has been shown to be associated with very low coronary risk. ACCURATE will test whether a CAC-first strategy (i.e., risk stratification, when CAC ≤ 1, to medical management or to cardiac PET stress testing), performed routinely in symptomatic patients presenting for evaluation of possible coronary artery disease (CAD) prior to the cardiac PET stress test, can be used as a gatekeeper for progression to the expensive rubidium-PET stress (regadenoson) perfusion scan and be a major cost-saver without adversely affecting patient care or outcomes. Routinely, qualifying patients undergo CACS when they present for evaluation of possible but unknown CAD status and are referred for cardiac PET stress testing. In ACCURATE, those with CACS≤1 will then be consented and randomized to either a cardiac PET stress test strategy or a non-PET-driven medical care strategy. Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not). Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up. All participating subjects' electronic medical records will be reviewed indefinitely for clinical outcomes. Initial outcomes will be reported at 1-year, 2-years, and 5-years, with future analyses to be determined by the study investigators. The objective of this study is to test the hypothesis that PET stress test strategy will results in a decreasing in major adverse cardiac endpoint without exceeding $100,000 per quality-adjusted life year compared to a CAC-first strategy for screening suspected/possible coronary artery disease.
Recruiting1 award N/A4 criteria
SomaSignal Tests
for Cardiovascular Disease Risk Management
This trial uses the SomaSignal Test to analyze blood samples and provide health information. It targets patients to see if this test can help guide medical decisions. The test works by examining proteins in the blood to give doctors useful health insights.
Recruiting1 award N/A8 criteria
More about Jeffrey Anderson
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jeffrey Anderson has experience with
- SomaSignal Test Results
- PET Stress Test
- Non-PET Medical Management
- Pelacarsen (TQJ230)
- Lepodisiran
Breakdown of trials Jeffrey Anderson has run
Cardiovascular Disease
Health Behaviors
Myocardial Ischemia
Coronary Artery Disease
Coronary Heart Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey Anderson specialize in?
Jeffrey Anderson focuses on Cardiovascular Disease and Health Behaviors. In particular, much of their work with Cardiovascular Disease has involved treating patients, or patients who are undergoing treatment.
Is Jeffrey Anderson currently recruiting for clinical trials?
Yes, Jeffrey Anderson is currently recruiting for 3 clinical trials in Salt Lake City Utah. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey Anderson has studied deeply?
Yes, Jeffrey Anderson has studied treatments such as SomaSignal Test Results, PET Stress Test, Non-PET Medical Management.
What is the best way to schedule an appointment with Jeffrey Anderson?
Apply for one of the trials that Jeffrey Anderson is conducting.
What is the office address of Jeffrey Anderson?
The office of Jeffrey Anderson is located at: Intermountain Medical Center, Salt Lake City, Utah 84107 United States. This is the address for their practice at the Intermountain Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.